These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16546533)

  • 21. Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection?
    Codreanu I; Perico N; Remuzzi G
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S34-8. PubMed ID: 15938031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetic nephropathy and renal protective agents.
    Marchiando R; Elston MP
    S D J Med; 1999 Oct; 52(10):385-6. PubMed ID: 10546516
    [No Abstract]   [Full Text] [Related]  

  • 23. [ACE and AT1 inhibitors in used in the progression of chronic renal failure].
    Switalski M
    Pol Arch Med Wewn; 2002 Apr; 107(4):379-87. PubMed ID: 12189931
    [No Abstract]   [Full Text] [Related]  

  • 24. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
    Cantarovich F; Rangoonwala B
    Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual blockade of the renin-angiotensin system in chronic renal disease: to do or not to do.
    Nakao N; Seno H; Kasuga H; Toriyama T; Kawahara H
    Clin Exp Nephrol; 2004 Sep; 8(3):183-7. PubMed ID: 15480894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetic nephropathy, percutaneous coronary interventions, and blockade of the renin-angiotensin system.
    Reinecke H; Matzkies F; Fobker M; Breithardt G; Schaefer RM
    Cardiology; 2005; 104(1):24-30. PubMed ID: 15942180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACE inhibitor use and the long-term risk of renal failure in diabetics.
    Woo KT; Lau YK; Wong KS; Chan CM
    Kidney Int; 2006 Oct; 70(7):1376-7; author reply 1378. PubMed ID: 16988741
    [No Abstract]   [Full Text] [Related]  

  • 28. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
    Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM
    Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
    Kujal P; Chábová VČ; Vernerová Z; Walkowska A; Kompanowska-Jezierska E; Sadowski J; Vaňourková Z; Husková Z; Opočenský M; Skaroupková P; Schejbalová S; Kramer HJ; Rakušan D; Malý J; Netuka I; Vaněčková I; Kopkan L; Cervenka L
    Clin Exp Pharmacol Physiol; 2010 Dec; 37(12):1159-69. PubMed ID: 20880190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toward better renoprotection: lessons from angiotensin receptor blockers.
    Miyata T; Takizawa S
    Hemodial Int; 2007 Apr; 11(2):164-8. PubMed ID: 17403166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
    Weir MR
    Postgrad Med; 2009 Jan; 121(1):96-103. PubMed ID: 19179817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACE inhibitor use and the increased long-term risk of renal failure in diabetes.
    Hamming I; Goor Hv; Navis GJ
    Kidney Int; 2006 Oct; 70(7):1377-8; author reply 1378. PubMed ID: 16988743
    [No Abstract]   [Full Text] [Related]  

  • 34. Preserving the diabetic kidney.
    Poirier SJ
    J Fam Pract; 1998 Jan; 46(1):21-7. PubMed ID: 9451365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Renin-angiotensin-aldosterone system].
    Suzuki H
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():153-6. PubMed ID: 15250285
    [No Abstract]   [Full Text] [Related]  

  • 36. [Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?].
    Barnas U; Mayer G
    Wien Klin Wochenschr; 1995; 107(1):10-4. PubMed ID: 7871784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is dual RAAS blockade useful in diabetic nephropathy?
    Wu MA; Perego F;
    Intern Emerg Med; 2014 Aug; 9(5):589-91. PubMed ID: 24846585
    [No Abstract]   [Full Text] [Related]  

  • 38. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade.
    Griffin KA; Bidani AK
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1054-65. PubMed ID: 17699327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H; O'Keefe J
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progression of chronic kidney disease: can it be prevented or arrested?
    Jaber BL; Madias NE
    Am J Med; 2005 Dec; 118(12):1323-30. PubMed ID: 16378772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.